Reaktion #425090

ord-76306a6d24734d9b8f7ac6f2683af088

Reaktionsgleichung

Cn1cccn1
1-methylpyrazole
[Li][CH2]CCC
n-butyl lithium
c1ccc(CO[C@@H]2CC[C@@H]3O[C@@H]3C2)cc1
(1R*,3R*,6S*)-3-(benzyloxy)-7-oxabicyclo[4.1.0]heptane
Cn1nccc1[C@H]1C[C@H](OCc2ccccc2)CC[C@@H]1O
title compound
Ausbeute 37.0%
Cn1nccc1[C@H]1C[C@H](OCc2ccccc2)CC[C@@H]1O
(1S*,2R*,4R*)-4-(Benzyloxy)-2-(1-methyl-1H-pyrazol-5-yl)cyclohexanol
Ausbeute 37.0%

Lösungsmittel

Reaktionsbedingungen

Detaillierte Bedingungen
See reaction.notes.procedure_details.

Aufarbeitung

  1. 1
    SonstigeThe reaction and aftertreatment

Vorschrift

The reaction and aftertreatment were conducted in the same manner as in Example 4a by using 1-methylpyrazole (650 mg, 7.92 mmol), n-butyl lithium (2.69 M solution in hexane; 3.08 mL, 8.28 mmol), (1R*,3R*,6S*)-3-(benzyloxy)-7-oxabicyclo[4.1.0]heptane (Bioorg. Med. Chem. 2004, 12, 1459; 1.54 g, 7.54 mmol) and THF (45 mL), to yield the title compound (790 mg, 37%) as a colorless solid.

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US08889741B2uspto-grants-2014_11